.Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B06A_OtherHematologicalAgents.B06AC02_Icatibant.Icatibant .Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B06A_OtherHematologicalAgents.B06AC02_Icatibant.Icatibant| name: | Icatibant |
| ATC code: | B06AC02 | route: | subcutaneous |
| n-compartments | 2 |
Icatibant is a selective bradykinin B2 receptor antagonist used primarily for the treatment of acute attacks of hereditary angioedema (HAE) in adults. It is currently approved and in clinical use for this indication.
Pharmacokinetic parameters obtained from healthy adult volunteers, both male and female, after single subcutaneous administration.
Wang, Y, et al., & Martin, P (2021). Population Pharmacokinetics and Exposure-Response Analyses to Guide Dosing of Icatibant in Pediatric Patients With Hereditary Angioedema. Journal of clinical pharmacology 61(4) 555–564. DOI:10.1002/jcph.1768 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33091166
Hide, M, et al., & Ishida, K (2023). Safety, efficacy, and pharmacokinetics of icatibant treatment in Japanese pediatric patients with hereditary angioedema: A phase 3, open-label study. The Journal of dermatology 50(11) 1473–1477. DOI:10.1111/1346-8138.16883 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37381768